Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Novel Insights from Clinical Practice

Bilateral Hypopyon Uveitis in Chronic Myeloid Leukemia

Tyagi M.a · Govindhari V.a · Pappuru R.R.a · Ambiya V.b

Author affiliations

aKanuri Santhamma Center for Vitreo-Retina Services, L.V. Prasad Eye Institute, Hyderabad, and bArmy College of Medical Sciences, New Delhi, India

Related Articles for ""

Ocul Oncol Pathol 2018;4:12-15

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Novel Insights from Clinical Practice

Received: February 15, 2017
Accepted: April 10, 2017
Published online: June 03, 2017
Issue release date: December 2017

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 0

ISSN: 2296-4681 (Print)
eISSN: 2296-4657 (Online)

For additional information: https://www.karger.com/OOP

Abstract

Background: A leukemic hypopyon is considered an early sign of central nervous system involvement or systemic relapse. A differential diagnosis of masquerade syndromes should be considered in cases of hypopyon uveitis that are atypical or unresponsive to treatment. We report a case of a 45-year-old man who presented with bilateral hypopyon uveitis and was subsequently diagnosed as having chronic myeloid leukemia. Method: Retrospective case review. Results: A 45-year-old diabetic male presented with diminished vision in both eyes for 10 days. Ophthalmic evaluation revealed rubeosis iridis, hypopyon, and signs of proliferative diabetic retinopathy with panretinal laser photocoagulation scars. He subsequently presented 1 week later with a bloodstained hypopyon in his right eye and a persistent hypopyon in his left eye. A peripheral blood smear and subsequent bone marrow trephine biopsy confirmed the diagnosis of chronic myeloid leukemia in blast crisis and he was referred to an oncologist for further management. Conclusion: A recalcitrant or atypical hypopyon uveitis can be an indicator of a blast crisis or a central nervous system involvement or sign of a relapse in cases of leukemia. The presence of unusual bloodstained hypopyon helped in identifying the presence of chronic myeloid leukemia and aided in a prompt oncology consultation.

© 2017 S. Karger AG, Basel


References

  1. Kincaid MC, Green WR: Ocular and orbital involvement in leukemia. Surv Ophthalmol 1983;27:211-232.
  2. Decker EB, Burnstine RA: Leukemic relapse presenting as acute unilateral hypopyon in acute lymphocytic leukemia. Ann Ophthalmol 1993;25:346-349.
    External Resources
  3. Ramsay A, Lightman S: Hypopyon uveitis. Surv Ophthalmol 2001;46:1-18.
  4. Ayliffe W, Foster CS, Marcoux P, et al: Relapsing acute myeloid leukemia manifesting as hypopyon uveitis. Am J Ophthalmol 1995;119:361-364.
  5. Santoni G, Fiore C, Lupidi G, et al: Recurring bilateral hypopyon in chronic myeloid leukemia in blastic transformation. A case report. Graefes Arch Clin Exp Ophthalmol 1985;223:211-213.
  6. Lipton JH, McGowan HD, Payne DG: Ocular masquerade syndrome in lymphoid blast crisis of chronic myeloid leukemia. Leuk Lymphoma 1995;20:161-163.
  7. Sudharshan S, Kumari A, Biswas J: Bilateral hypopyon as the presenting feature of chronic myeloid leukemia. Ocul Immunol Inflamm 2008;16:244-246.

Article / Publication Details

First-Page Preview
Abstract of Novel Insights from Clinical Practice

Received: February 15, 2017
Accepted: April 10, 2017
Published online: June 03, 2017
Issue release date: December 2017

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 0

ISSN: 2296-4681 (Print)
eISSN: 2296-4657 (Online)

For additional information: https://www.karger.com/OOP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.